Articles tagged with Pancreatic Cancer
The American College of Surgeons' annual cancer report reveals that breast, bladder, and pancreatic cancers are increasingly treated with personalized therapies before surgery. Cancer stage at diagnosis remains a significant factor in determining patient survival rates.
Dr. Direna Alonso-Curbelo's ERC Consolidator Grant project, IGNITE, aims to unravel the complex interplay between genetic and non-genetic factors that ignite tumor development. The research focuses on understanding how inflammation drives pancreatic cancer initiation and progression.
Min Li will receive the 2024 Palade Prize for his contributions to pancreatology, recognizing his pioneering work on pancreatic cancer and metabolic reprogramming. He has been continuously funded by the National Cancer Institute for 15 years and has published over 200 high-impact articles.
MSK researchers have identified a compound that selectively kills glioblastoma cells while sparing healthy cells. They also developed a new method to study cancer evolution by introducing mutations in specific genes, allowing for the rapid regression of leukemia and understanding its behavior.
An analysis of pancreatic cancer data found an increasing incidence among young adults, but stable mortality rates, suggesting detection of previously undetected disease. The study highlights the need for caution against overdiagnosis and high-risk surgery.
A randomized phase 2 clinical trial shows that adding high-dose, intravenous vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from eight months to 16 months. Patients also experience improved quality of life with reduced side effects.
Researchers at UC Riverside develop a novel method to degrade the Pin1 protein, which is involved in pancreatic cancer development. The 'molecular crowbar' strategy has the potential to target and break down harmful proteins, offering new hope for cancer therapy.
The National Comprehensive Cancer Network has updated its guidelines for genetic/familial high-risk assessment, incorporating the latest scientific research and expert recommendations to enhance screening practices and treatment options. The expanded guidelines cover various cancer types and provide guidance on genetic testing, heredit...
Recent advancements in diagnostic techniques, including artificial intelligence integration, biomarker discoveries, and imaging technologies, have transformed the detection of pancreatic cancer. Key findings include improved sensitivity and accuracy of early-stage lesion identification using AI models, as well as the discovery of novel...
Researchers document remarkable response to pembrolizumab in patient with metastatic adenosquamous pancreatic cancer (ASCP) and KRAS G12C mutation. The study highlights potential shift in treatment of ASCP, a rare form of pancreatic cancer traditionally underserved by current therapies.
Researchers discovered that INPP4B drives the movement of lysosomes to the periphery of pancreatic cancer cells, releasing their contents into the extracellular space and disrupting the structural support network. This process enables the cells to migrate and invade other tissues, making it easier for the cancer to spread.
A new survey by Ohio State University shows that most people believe pancreatic disease affects only the elderly and that there is nothing they can do to reduce their risk. However, obesity increases lifetime risk for pancreatic cancer by 20%.
Researchers at the Hebrew University of Jerusalem have developed a highly selective inhibitor for Matrix Metallopeptidase 7 (MMP7), an enzyme crucial for cancer spread and progression. The novel peptide D'20 demonstrates remarkable stability and selectivity, targeting MMP7 while leaving similar enzymes unaffected.
A systematic review and meta-analysis found that weight-loss surgery reduces pancreatic cancer risk among individuals with obesity by 44%, and among those with both obesity and type 2 diabetes by 79%. The study suggests that metabolic-bariatric surgery may play a crucial role in reducing the risk of pancreatic cancer.
A new experimental blood test, combining CA199.STRA and CA19-9 biomarkers, improves accurate detection of pancreatic cancer in a lab setting by 27%, according to a recent study published in Cancer Letters. The test's effectiveness in a clinical lab setting is crucial for approval as a potential diagnostic method.
A multicenter study found that specific KRAS mutations in pancreatic cancer can affect patient outcomes, with some variants associated with better overall survival. The research suggests revising clinical guidelines to recommend routine molecular testing in all patients with pancreatic cancer.
Researchers at WVU are working on a project to inhibit the myeloperoxidase enzyme, which feeds pancreatic cancer growth. By targeting this enzyme, they hope to boost the body's immune system to fight cancer, showing promise in mouse models and potential for future clinical trials.
A new AI model generates detailed images of cancer tissue that imitate what its staining would look like, reducing the need for resource-intensive lab analyses. The VirtualMultiplexer uses contrastive unpaired translation to create accurate virtual pictures of diagnostic tissue colorations.
Researchers found that omitting the bolus-specific 5-fluorouracil (5-FU) portion from common chemotherapy regimens improves tolerability without sacrificing treatment effectiveness. The study of 11,765 patients shows no decrease in overall survival but a notable reduction in cytopenias.
A new study by Cedars-Sinai Cancer investigators found that most patients with stage 1 and stage 2 pancreatic cancer are upstaged after surgery. Lymph node involvement is often missed in the staging process, leading to inaccurate diagnoses and poorer survival rates.
The study used spatial transcriptomics and machine learning to analyze gene expression and cell distribution in PanINs, identifying key features of pancreatic cancer progression. Key findings include increased cell proliferation and decreased inflammatory signaling in high-grade PanIN lesions.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Researchers have developed a novel nanoparticle drug-delivery system to activate an immune pathway in combination with tumor-targeting agents, showing promising results in treating pancreatic cancer. Eight out of nine mice tested experienced tumor improvements, including two complete responses.
Researchers have discovered a new approach to treating pancreatic ductal adenocarcinoma (PDAC), a rare type of pancreatic cancer. Folinic acid has been found to weaken the cancer's defenses by elevating levels of anti-cancer immune molecules, enabling a more effective immune response and slower tumor growth.
Researchers from Osaka University have developed a humanized antibody that blocks the DKK1–CKAP4 pathway, stimulating cancer cell growth. The new anti-CKAP4 antibody suppressed tumor formation in mice with both human and mouse tumors, as well as modulating anti-tumor immune reactions.
The study analyzes six major digestive system cancers worldwide and in China, revealing correlations between country HDI and cancer prevalence. Colorectal cancer is the most prevalent, while Asia accounts for 60.5% of new gastrointestinal cancer cases globally.
Scientists discovered a way to kill pancreatic cancer in mice by combining a ketogenic diet with an existing cancer drug. The diet blocks the cancer's only source of fuel, allowing the drug to take effect and shrink tumors. This finding opens a new vulnerability for treating cancer with diet and personalized therapies.
A new method for detecting pancreatic cancer has been introduced using glycopeptide probes that selectively detect specific antibodies in blood samples. These probes mimic tumor-associated antigens and show promise for early detection screenings.
Researchers identified a potential antigen for TCR recognition in melanoma, suggesting that RNLS protein could be recognized by T cells leading to local immune responses against the cancer. The study found that chemical complementarity between melanoma-resident TCR CDR3s and renalase-1 protein correlates with increased melanoma survival.
Researchers found that adding metastasis-directed radiation therapy to standard chemotherapy improved progression-free survival by 7.8 months in patients with oligometastatic pancreatic cancer. The approach also showed increased immune responses and longer survival times.
Researchers found that abnormal results from routine blood tests were linked to a higher risk of being diagnosed with cancer within a year. The study estimated that taking these results into account could lead to an extra six people with undiagnosed cancer being urgently referred for treatment.
A Mayo Clinic study reveals that current genetic screening protocols fail to detect notable numbers of people carrying hereditary breast and ovarian cancer syndrome and Lynch syndrome mutations. The study identified 550 carriers of these mutations, with half being previously unaware of their risk.
Researchers at Memorial Sloan Kettering Cancer Center have identified a new mechanism of resistance to KRAS inhibitors in pancreatic cancer, suggesting an opportunity to make the treatment more effective. The study found that a more aggressive subtype of pancreatic tumor is likely to respond well to KRAS inhibitors.
Researchers from Leiden University discuss targeting ABC transporters in pancreatic ductal carcinoma (PDAC), a cancer with poor survival rates. The authors highlight the potential of inhibiting ABC transporters to overcome chemoresistance and suggest developing stratification protocols to identify patients most likely to benefit.
Researchers identified nidogen-2 as a key driver of pancreatic cancer progression and metastasis. Blocking this molecule enhanced chemotherapy effectiveness and reduced spread in mouse models, suggesting a promising new treatment approach.
Scientists at Stanford University discovered that pancreatic cancer cells become resistant to chemotherapy due to stiff tissue and high hyaluronic acid levels. By altering the matrix, they found it possible to make cancer cells sensitive to chemotherapy again.
The article reviews recent advances in applying artificial intelligence to oncology, showcasing promising improvements in cancer care. The authors emphasize the need for interdisciplinary collaboration, rigorous validation, and ethical principles to harness AI's potential.
Researchers at Weill Cornell Medicine have identified cellular and molecular markers that can predict when pancreatic cancer will spread to the liver or other organs. The study found that patients with early-stage pancreatic cancer who showed signs of immune exhaustion were more likely to develop liver metastases.
Researchers at Johns Hopkins Medicine have developed a 3D genomic profiling technique to identify small precancerous lesions in the pancreas, which can lead to aggressive pancreatic cancers. The study provides the most detailed 3D map of precancerous lesions in the human pancreas to date.
A new study found that nearly five percent of pancreatic adenocarcinoma patients achieve a pathological complete response (pCR) after treatment, leading to a 63% 5-year survival rate. The research highlights the importance of tailoring treatment based on factors such as chemotherapy regimens and radiation therapy.
Researchers have discovered that a protein called MED12 plays a critical role in pancreatic cancer's development, particularly in basal-like cells. The study builds on decades of research at Cold Spring Harbor Laboratory, which previously identified the importance of p63 for basal cell formation.
A comprehensive molecular portrait of KRAS has been established, revealing its key role in pancreatic cancer progression and resistance to treatment. The study identifies ERK as a critical regulator of KRAS activity, with implications for developing targeted therapies.
A team of researchers has identified the CDA gene as a key player in immunotherapy resistance in pancreatic cancer. Inhibiting this gene improves T-cell infiltration and increases the effectiveness of immunotherapy in a type of pancreatic cancer called PDAC.
Researchers developed a human pancreatic cancer fibrotic barrier model to assess treatment strategies and test efficacy of therapeutic interventions. Inhibition of ROCK2 pathway resulted in reduced ECM remodeling and improved tissue permeability for drugs, highlighting its potential for enhancing drug delivery in PDAC.
A new study found that combining histone deacetylase inhibitors, poly (ADP ribose) polymerase inhibitors, and decitabine resulted in synergistic cytotoxicity in all cell lines tested. This combination impaired DNA repair pathways and altered epigenetic regulation of gene expression.
A quality improvement analysis found that many US residents live within 30 miles of a clinical trial site, highlighting disparities in access. The study highlights concerns about equity and fairness in healthcare resource distribution, particularly for marginalized communities.
The phase 2 clinical trial of BXCL701 in combination with pembrolizumab showed a 50% progression-free survival rate and significant reductions in CA19-9 markers, indicating potential anti-cancer effects. The treatment has also shown low blood pressure as the main side effect.
Researchers found that statins, specifically pitavastatin, can suppress inflammation in the skin and pancreas by blocking interleukin-33 production. This inhibition reduces the risk of chronic pancreatitis and pancreatic cancer.
Researchers at Hollings Cancer Center have identified a promising therapeutic strategy to combat pancreatic cancer. By simultaneously blocking HSP70 and autophagy, the growth of pancreatic tumors can be slowed, offering new hope for treatment.
Researchers found that ARID1A mutation renders tumors sensitive to immunotherapy by triggering an antiviral immune response. This could lead to improved patient outcomes and the development of targeted therapies.
Researchers have developed a breakthrough therapy that can adapt CAR-T cell therapy to target solid tumors, potentially transforming cancer treatment. The therapy uses a novel antibody and costimulatory protein to activate T cells, overcoming the challenges of immune suppression in solid tumors.
Researchers at the University of Wisconsin-Madison have developed a novel approach to treating pancreatic cancer using nano-drugs delivered via bacteria. The treatment bypasses the dense collagen barrier surrounding tumors, allowing for more effective delivery of immunotherapies.
Researchers discovered that the anatomical location of pancreatic tumors impacts treatment outcomes, suggesting a tumor-location-based model for improving patient care. The findings may lead to more specific treatment plans and better immunotherapy effectiveness.
The ECOG-ACRIN Cancer Research Group will present late-breaking findings on prostate cancer, breast cancer, and pancreas cancer at ASCO 2024. These studies include optimal chemotherapy for Black women with breast cancer and results from the first randomized national trial in older adults with pancreas cancer.
A new case report uses longitudinal multi-omics monitoring to detect a precancerous pancreatic tumor in a patient. The study highlights the potential of blood-based LMOM for early detection and personalized medicine, warranting further translational research.
Researchers discovered that liver cells secrete SAA proteins, which hinder T cell infiltration and attack tumors. Deleting SAA proteins increased survival times and likelihood of cures in mice with pancreatic tumors.
The PRECEDE study found that nearly 80% of participants in the highest-risk cohort completed baseline imaging, highlighting the feasibility of improving early detection and prevention for pancreatic cancer. Researchers recommend sorting individuals into three groups based on family history and genetic mutations to tailor surveillance.
A new study reveals that 'crosstalk' between pancreatic cancer cells and macrophages is the first step towards the onset of cachexia. The research provides evidence of an underlying mechanism for the development of this debilitating muscle-wasting condition, which affects pancreatic cancer patients.
The National Science Foundation has awarded Amplified Sciences a $275,000 Phase 1 Small Business Innovation Research grant to develop novel ultrasensitive optical reporter platform technology for early detection of pancreatic cancer. The company aims to improve diagnosis and treatment outcomes with its multiplexing capabilities.
A novel exosome-based liquid biopsy approach has been developed to detect pancreatic cancer at early stages. The method combines eight microRNAs uniquely found in exosomes shed from pancreatic cancers with five cell-free DNA markers, achieving a 97% detection rate for stage 1-2 cases.